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Abstract
Glioblastoma multiforme (GBM) is the most aggressive brain tumor that, by virtue of its resistance
to chemo- and radiotherapy, is currently incurable. Identification of molecules whose targeting may
eliminate GBM cells and/or sensitize glioblastoma cells to cytotoxic drugs is therefore urgently
needed. CD44 is a major cell surface hyaluronan receptor and cancer stem cell marker that has been
implicated in the progression of a variety of cancer types. However, the major downstream signaling
pathways that mediate its pro-tumor effects and the role of CD44 in the progression and GBM
chemoresponse of GBM have not been established. Here we show that CD44 is up-regulated in GBM
and that its depletion blocks GBM growth and sensitizes GBM cells to cytotoxic drugs in vivo.
Consistent with this observation, CD44 antagonists potently inhibit glioma growth in preclinical
mouse models. We provide the first evidence that CD44 functions upstream of the mammalian Hippo
signaling pathway and that CD44 promotes tumor cell resistance to reactive oxygen species- and
cytotoxic agent-induced stress by attenuating activation of the Hippo signaling pathway. Together,
our results identify CD44 as a prime therapeutic target for GBM, establish potent anti-glioma efficacy
of CD44 antagonists, uncover a novel CD44 signaling pathway, and provide a first mechanistic
explanation as to how up-regulation of CD44 may constitute a key event in leading to cancer cell
resistance to stresses of different origins. Finally, our results provide a rational explanation for the
observation that functional inhibition of CD44 augments the efficacy of chemo- and radiation
therapy.
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Introduction
It is now well established that the host tissue microenvironment provides an essential
contribution to cancer progression and modulates the response of cancer cells to treatments,
implying that elements within the tumor microenvironment constitute potentially important
targets for anti-cancer therapy (1–4). The tumor microenvironment consists of resident and
infiltrating host cells as well the components of the extracellular matrix (ECM). Physical
interactions and functional cross-talk between tumor cells and their microenvironment are
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mediated primarily by cell surface receptors that are responsible for the cell-cell and cell-ECM
adhesion thereby providing potentially attractive therapeutic targets (5).
Malignant gliomas is the most common type of primary brain cancer and the most malignant
being grade IV astrocytoma, also known as glioblastoma multiforme (GBM) (6). Despite
aggressive multimodal therapy, GBM remains incurable, with an estimated median survival
of less than 1 year and with less than 3% of patients surviving longer than 5 years (6–7).
Identification of new therapeutic targets and means to improve the efficacy of existing forms
of therapy are therefore urgently needed. The central nervous system contains elevated levels
of glycosaminoglycan hyaluronan (HA) (8) and glioma cells express the major cell surface HA
receptor, CD44 (9), which is implicated in diverse cellular functions (10–12). CD44 is up
regulated in a broad range of malignant tumors and its elevated expression correlates with poor
prognosis of some cancer types (9–12). CD44 plays an important role in melanoma (13–14)
and breast cancer (15–17) growth and progression but little is known about its contribution to
the progression of GBM and the response of GBM cells to chemotherapy. CD44 has been
associated with numerous signaling events and serves as a co-receptor of several receptor
tyrosine kinases (RTKs) (9–12) but no single major downstream signaling pathway of CD44
has been defined to date.
The cytoplasmic domain of CD44 interacts with ezrin-radixin-moesin (ERM) family proteins
(18) and merlin (19–20), which serve as linkers between cortical actin filaments and the plasma
membrane (21–22). In Drosophila, merlin functions upstream of the Hippo (Hpo) signaling
pathway that plays an important role in restraining cell proliferation and promoting apoptosis
(23–26). Although still incompletely characterized, the Hippo pathway is believed to be
conserved in mammals (27–28). Mammalian homologs of Hpo, Warts (Wts), Yorkie (Yki),
and dIAP are, respectively, Mammalian Sterile Twenty-like (MST) kinase1 and 2 (MST1/2)
(26,29), Large tumor suppressor homolog 1 and 2 (Lats1 and 2) (30), Yes-Associated Protein
(YAP) (31), and cellular Inhibitor of Apoptosis (cIAP1/2)(28). However, the upstream
components of the mammalian Hippo signaling pathway have not been identified.
We have shown recently that merlin activates the Lats2 signaling pathway in human
glioblastoma cells, sensitizes the response of GBM cells to chemotherapeutic agents, and
inhibits GBM growth in vivo (27) and that merlin exerts its tumor suppressor function by
inhibiting the hyaluronan-CD44 interaction (32). We therefore addressed the possibility that
CD44 may play a potentially important role in malignant glioma growth, progression, and
response to chemotherapy by regulating the mammalian Hippo signaling pathway. Our results
demonstrate that CD44 is up-regulated in human GBM and that knockdown of CD44
expression inhibits GBM cell growth and/or sensitizes GBM cells to cytotoxic drugs in vivo.
Moreover, we provide the first evidence that CD44 functions upstream of mammalian Hippo
signaling pathway and protects GBM cells from reactive oxygen species (ROS) and cytotoxic
agent-induced stress and apoptosis by attenuating the activity of the entire Hippo signaling
pathway and that of the downstream JNK/p38 kinases and by decreasing induction of p53
expression. We further demonstrate that purified soluble CD44-Fc fusion proteins potently
inhibit growth of pre-established intracranial GBM in mice and significantly extend survival
of the animals. Our results thus identify CD44 as an important therapeutic target for GBM and
help establish CD44 antagonists as potent anti-GBM agents. They also uncover the first
candidate signaling pathway whose activation appears to be directly dependent on CD44
dysfunction, and provide a mechanistic basis for CD44 involvement in GBM progression and
chemoresistance.
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Materials and Methods
Patient Glioma Samples and Reagents
The glioma tissues were obtained from Cooperative Human Tissue Network (CHTN). Anti -
MST1/2, -Lats1/2 (Bethyl Lab), -CD44, -Erk1/2, -AKT, -JNK, -p21, -p38, -p53, -cIAP1/2, and
-merlin (Santa Cruz), -actin (Sigma), -v5 epitope, -phospho-merlin, -puma (Invitrogen), -
cleaved caspase 3, -phospho-Erk1/2, -phospho-AKT, -phospho-JNK, -phospho-p38, -
phospho-MST1/2, -phospho-Lats1, -phospho-YAP (Cell signaling), -YAP, -phospho-Lats2
(Abnova), and –heparan sulfate (HS, CalBiochem) antibodies were used in the experiments.
Apoptag kit was from Chemicon and anti-Brdu from Roche.
CD44-Fc Fusion Expression Constructs, Mutagenesis, and Knockdown Constructions
Three human soluble CD44-Fc (hsCD44) fusion proteins were generated by fusing the
extracellular domain of human CD44v3-v10, CD44V8-v10, or CD44s to the constant region
(Fc) of human IgG1. R41A mutants of these CD44-Fc fusion proteins were generated using
the QuikChange™ mutagenesis kits (Stratagene) as described (16). Several shRNAmir and
TRC constructs against human CD44 and a non-targeting shRNAmir and a non-targeting TRC
control shRNA were obtained from Open Biosystems and Addgene.
Production and Purification of Soluble CD44-Fc and Soluble CD44R41A-Fc Fusion Proteins
COS-7 cells infected with the retroviruses carrying hsCD44v3-v10-Fc, hsCD44v8-v10-Fc,
hsCD44s-Fc, hsCD44v3-v10R41A-Fc, hsCD44v8-v10R41A-Fc, and hsCD44sR41A-Fc
constructs were cultured in RPMI medium containing 10% fetal bovine serum (FBS) until
confluence and were then switched to serum free RPMI medium (SFM) for an additional three
days of culture. The conditioned cell culture medium was retrieved and the fusion proteins
purified on protein A columns (GE Healthcare Biosciences). Before elution from protein A
column, some of preparations of the bound CD44-Fc fusion proteins were treated heparinase
I (10 units/ml) and heparinase III (2 unit/ml) at 37 °C for 4 h.
Western Blot Analysis, Immunocytochemistry, and Fluorescein-labeled HA (FL-HA) Binding
Assay
Western blots and immunocytochemistry were performed as described (27,32). To assess FL-
HA binding, GBM cells were cultured in 35-mm dishes for 24–48 h; 20 µ;g/ml FL-HA was
added to the cultured cells for an additional 12 h. The FL-HA binding assay was performed as
described previously (33).
Subcutaneous and Intracranial Tumor Growth Experiments, and Bioluminescence Imaging
Analysis of the Intracranial Gliomas
Mice were used in accordance with the approved IACUC Protocol. Pooled populations of
transduced U87MG and U251 glioma cells were used in subcutaneous and intracranial tumor
growth experiments as described (27). Briefly, 2 or 5 ×106 glioma cells were injected
subcutaneously into each immunocompromised B6.129S7-Rag1tmMom (Rag1, Jackson Lab)
mouse. For the intracranial tumor growth experiments, U87MG (4×105cells in 10µl HBSS/
Rag1 mouse)/U251 cells (2×105cells in 10µl HBSS/Rag1 mouse) were injected as described
(27). Following the injections, mice were monitored closely and the duration of their survival
was recorded. Mice that showed signs of distress and morbidity were euthanized and considered
as if they had died on that day. Survival rates were calculated as follows: survival rate (%) =
(number of mice still alive/total number of experimental mice) × 100%. Bioluminescence-
imaging approach is used to monitor the growth of intracranial gliomas in live animal as
described (27) using IVIS-200 imaging system (Xenogen). Images were obtained 12min after
injection of D-luciferin using the same intensity scaling.
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Statistics
One-way ANOVA statistical analyses were performed to analyze differences of the tumor
volumes and growth rates between the control and experimental groups. LogRank analyses
were performed for the survival experiments. Differences were considered statistically
significant at p<0.05.
Results
CD44 is up regulated in human GBM
To determine CD44 expression level in GBM, we mined available gene expression datasets at
www.oncomine.org (34). In all four independent datasets, CD44 transcripts were consistently
up regulated in human GBM compared to either normal brain (Fig 1A, studies 1, 2, and 4)
(35–37) or normal white matter (study 3)(38). In addition, immunohistochemistry analysis of
paraffin sections of primary tumors showed that CD44 was up regulated in all 14 GBM cases
analyzed compared to eight cases of normal human brain (Fig 1B and data not shown).
To address the role of CD44 in GBM growth and progression, we analyzed CD44 protein levels
in a variety of human glioma cell lines. We found that the majority of the glioma cells tested
express higher levels of CD44 than normal human astrocytes (NHAs) and that the standard
85–90 kDa form (CD44s, Fig 1C) is the predominant isoform expressed. Based on their high
CD44 expression level and their tumorigenicity in immunocompromised mice, U87MG and
U251 glioma cells were selected to investigate how CD44 contributes to GBM growth and
progression.
Lenti-viral based shRNAs effectively knock down CD44 expression in human GBM cells
To knock down endogenous CD44 expression in GBM cells, we screened a set of human CD44-
specific shRNA constructs (shRNA-TRC-CD44#1-#5 and shRNAmir-CD44#1-#3, Open
Biosystems) Non-targeting (NT) control shRNAs (shRNA-TRC-NT and shRNAmir-NT) were
included as the negative controls. We found that two out of three shRNAmirs (shRNAmir-
CD44#1 and #3) and 1–2 TRC-shRNA (shRNA-TRC-CD44#3 and/or #4) knocked down
CD44 expression efficiently in the U87MG and U251 GBM cells, as assessed by real-time
qPCRs (data not shown), western blot analysis (supplemental Fig 1A), and
immunocytochemistry (supplemental Fig 1B) whereas non-targeting controls displayed no
effect. Furthermore, effective knockdown of CD44 expression dramatically reduced binding
and endocytosis of FL-HA, whereas non-targeting shRNAs had no effect (supplemental Fig
1C).
Knockdown of CD44 expression inhibits subcutaneous growth of GBM cells by inhibiting
their proliferation and promoting their apoptosis in vivo
Pooled populations of the transduced U87MG and U251 cells with different degrees of CD44
depletion were used in subcutaneous (s.c.) tumor growth experiments. Decreased CD44
expression in these cells correlated with reduced tumor volume (Fig 2A) and significantly
reduced growth rates in vivo (Fig 2B). We observed that the shRNAs that knocked down CD44
expression, but not the non-targeting shRNAs, inhibited glioma cell proliferation (Fig 2C,
middle panels) and promoted apoptosis in vivo (Fig 2C, bottom panels), consistent with the
notion that CD44 plays an important role in regulating GBM cell growth and survival.
Knockdown of CD44 expression inhibits intracranial GBM growth
To determine how CD44 knockdown affects intracranial glioma growth, the double drug-
resistant pooled populations of U87MG-Luc/U251-Luc cells that express luciferase and
display efficient CD44 knockdown were injected intracranially into Rag-1 mice. We found
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that suppression of CD44 expression significantly inhibited intracranial tumor growth and
extended the survival of the experimental mice compared to the animals injected with U87MG/
U251-Luc cells transduced with non-targeting shRNAs (Fig 3A–B).
Reduced CD44 expression sensitizes GBM cells to cytotoxic drugs in vivo
The first-line cytotoxic drugs for GBM are temozolomide (TMZ) and carmustine (BCNU). We
therefore investigated whether reduced CD44 expression sensitizes glioma cells to BCNU and
TMZ treatment in vivo. We observed that BCNU and TMZ displayed a weak and a moderate
inhibitory effect on the glioma growth, respectively, when used as single agents (Fig 3C).
However, CD44 depletion sensitized the response of U87MG and U251 GBM cells to BCNU
and TMZ and the combination of CD44 knockdown and treatment with BCNU or TMZ resulted
in a synergistic inhibition of intracranial glioma progression as determined by markedly
prolonged median survival of the experimental mice (Fig 3D).
CD44 attenuates activation of the mammalian equivalent of Hippo signaling pathway and
plays a key role in regulating stress and apoptotic responses of human GBM cells
Radiation therapy and some cytotoxic agents generate reactive oxygen species (ROS) that
constitute a major inducer of cell death and underlie their anti-glioma effects. To address the
molecular mechanisms that underlie the observed chemosensitizing effect of CD44 depletion
on glioma cells, we investigated how reduced CD44 expression affects GBM cell response to
oxidative stress induced by H2O2 and cytotoxic stress induced by TMZ. Our results showed
that the GBM cells depleted of CD44 responded to oxidative stress with robust and sustained
phosphorylation/activation of MST1/2 and Lats1/2, phosphorylation/inactivation of YAP, and
reduced expression of cIAP1/2 (Fig 4A–B). These effects correlated with reduced
phosphorylation/activation of merlin, increased levels of cleaved caspase-3, and reduced cell
viability (Fig 4B and 2C, and data not shown). By contrast, high expression of endogenous
CD44 promoted phosphorylation/inactivation of merlin, attenuated stress induced activation
of entire mammalian equivalent of Hippo signaling pathway, and up-regulated cIAP1/2 leading
to inhibition of caspase-3 cleavage and apoptosis (Fig 4A, 2C, data not shown). Together, for
the first time, these results place CD44 upstream of the mammalian Hippo signaling pathway
(merlin-MST1/2-Lats1/2-YAP-cIAP1/2) and suggest a functional role of CD44 in attenuating
tumor cell responses to stress and stress-induced apoptosis.
Because MST1/2 kinases have multiple downstream effectors, we investigated whether known
effectors of MST1/2 also function downstream of the newly discovered CD44-MST1/2
signaling axis. Knockdown of CD44 was observed to result in elevated and sustained activation
of JNK and p38 stress kinases in U87MG cells exposed to oxidative stress, as well as sustained
up-regulation of p53, a known downstream effector of JNK/p38, and its target genes, p21 and
puma (Fig 4D). By contrast, GBM cells with high levels of endogenous CD44 displayed
transient and attenuated activation of JNK/p38 and induction of p53, p21, and puma (Fig 4C).
To address the mechanism whereby CD44 depletion sensitizes glioma cells to cytotoxic drugs
in vivo (Fig 3C–D), we performed experiments similar to those outlined in Figure 4 but using
TMZ instead of H2O2 to induce cytotoxic stress in U87MG cells expressing a high or low level
of CD44. Similar to their response to oxidative stress, GBM cells depleted of CD44 mounted
more robust and sustained activation of MST1/2 upon exposure to TMZ, along with
phosphorylation/inactivation of YAP that correlates with reduced levels of cIAPs, activation
of p38 but not JNK, and up-regulation p53 and its target gene p21 (Supplemental Fig 2).
Together, these results establish a novel CD44 signaling pathway and a novel role of CD44 in
inhibiting stress/apoptotic responses of tumor cells by attenuating activation of the mammalian
Hippo signaling pathway, and provide a first mechanistic explanation as to how up-regulation
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of CD44 in advanced/malignant cancers may constitute a key event in leading to their resistance
to stress of various origins, including host defense and therapeutic intervention.
CD44 modulates ErbB and c-Met receptor tyrosine kinase (RTK) mediated growth-signaling
pathways in glioma cells
Our in vivo results have shown that CD44 knockdown inhibits proliferation of GBM cells in
vivo (Fig 2C). Previous studies have shown that CD44 is a co-stimulator of ErbB and c-Met
RTK signaling pathways (12,39–40). To determine whether CD44 knockdown diminishes the
activation of downstream signaling pathways induced by EGF family ligand- and HGF in GBM
cells, we treated serum starved CD44-high or -low U87MG cells with EGF family ligands,
HGF, NGF, and 10% FBS. Our results showed that reduced CD44 expression diminished EGF
family ligand- and HGF- but not NGF- and FBS-induced phosphorylation of Erk1/2 kinase
but not that of AKT kinase (Fig 5), suggesting that CD44 preferentially modulates proliferation
but not survival signaling pathways activated by these growth factors.
Antagonists of CD44, hsCD44v3-v10-Fc, hsCD44v8-v10-Fc, and hsCD44s-Fc, serve as
effective therapeutic agents against human GBM in mouse models
To determine whether CD44 antagonists can be used to inhibit GBM progression in preclinical
mouse models, we developed several fusion proteins composed of the constant region of human
IgG1 (Fc) fused to the extracellular domain of human CD44v3-v10, CD44v8-v10, or CD44s.
Successful attempts to generate antagonists of RTKs and CD44 using this approach have been
reported (41–42). Receptor-Fc fusion proteins are believed to function by trapping ligands and/
or interfering with endogenous receptor functions.
U87MG and U251 cells were transduced with retroviruses carrying the expression constructs
encoding these CD44-Fc fusion proteins or empty expression vector. Pooled puromycin
resistance cells expressed high levels of hsCD44v3-v10-Fc, hsCD44v8-v10-Fc, and hsCD44s-
Fc fusion proteins (Fig 6A, supplemental Fig 3A). We first assessed whether the soluble CD44-
Fc fusion proteins are capable of altering FL-HA binding to endogenous GBM cell surface
CD44 and found that expression of the fusion proteins reduced binding of FL-HA to the GBM
cells (Supplemental Fig 3B). These cells were then compared to empty vector-transfected cells
for subcutaneous and intracranial growth in Rag-1 mice. hsCD44v3-v10-Fc, hsCD44v8-v10-
Fc, and hsCD44s-Fc expression markedly inhibited subcutaneous and intracranial growth of
U87MG and U251 cells and significantly extended survival of mice bearing the intracranial
tumors. The hsCD44v3-v10-Fc fusion protein displayed the most profound inhibitory effect
(Fig 6B and C).
CD44 plays an important role in regulating immune and inflammatory responses, which affect
tumor progression (43). Our experiments thus far were performed in Rag-1 mice that have
innate immunity but no mature T or B cells. To determine whether CD44-Fc fusion proteins
display similar anti-GBM activity in the mice with functional adaptive immunity, we assessed
their effect on intracranial growth of a mouse glioma cell, GL261, in immunocompetent mice.
GL261 cells form aggressive invasive intracranial tumors in syngeneic C57BL/6 mice that
have intact adaptive immunity. Overexpression of hsCD44-Fc proteins in GL261 cells
inhibited their intracranial growth in C57BL/6 mice similar to their effect on U87MG/U251
human GBM cells in Rag-1 mice (data not shown), suggesting that the results obtained were
not significantly affected by lack of the adaptive immunity in Rag-1 mice and are broadly
applicable.
The v3 exon of CD44 contains a Ser-Gly-Ser-Gly motif for covalent attachment of heparan
sulfate (HS) side chains (44). To assess whether hsCD44v3-v10-Fc proteins are modified by
HS, purified hsCD44s-Fc, hsCD44v8-v10-Fc, and hsCD44v3-v10-Fc fusion proteins were
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treated with or without heparinase I/III before elution from protein A columns. These proteins
were then coated on Elisa plates in triplicate. After blocking with BSA, the coated proteins
were tested for reactivity with anti-HS antibody. The intensity of the reaction, as assessed by
a colorimetric assay, was normalized by the reactivity with anti-CD44 antibody, which
provides relative quantity of the coated fusion proteins on the plates. Our results showed that
only hsCD44v3-v10-Fc was modified by HS and stained positively with anti-HS antibody. The
observed reactivity was sensitive to heparinase I/III treatment (supplemental Figure 3C).
CD44 has multiple ligands including HA, osteopontin, heparin binding growth factors,
fibronectin, serglycin, laminin, MMP-9, and fibrin (9–12,44) and cooperates with several
RTKs and other cell surface receptors (9,11,40). Many of CD44 functions are mediated through
its interaction with HA (12) that is abolished by the single R41A mutation (45). To determine
whether the CD44-HA interaction alone is responsible for the GBM promoting activity of
CD44, we generated pooled populations of U87MG and U251 cells expressing hsCD44sR41A-
Fc or hsCD44v3-v10R41A-Fc and compared their anti-GBM effects with that of the wild type
counterparts. We showed that unlike wild type CD44-Fc fusion proteins, CD44R41A-Fc
proteins are incapable of inhibiting FL-HA binding to the GBM cells (supplemental Fig 3B
and data not shown). However, whereas hsCD44sR41A-Fc displayed a weak anti-GBM effect,
hsCD44v3-v10R41A-Fc retained a substantial level of anti-GBM activity (Fig 6 C right panel
and data not shown), consistent with our earlier observations that hsCD44v3-v10-Fc fusion
protein exerts the most potent anti-GBM effect of the three CD44-Fc fusion proteins tested,
suggesting a mechanism of action in addition to trapping HA. Together, these results suggest
that CD44, and especially CD44 variants, promote tumor progression both in a HA dependent
and HA-independent fashion.
Finally, we assessed the anti-GBM efficacy of purified hsCD44s-Fc fusion proteins in pre-
established intracranial gliomas resulting from injection of 5–105 U87MG or U251 cells into
Rag-1 mice. Intracranial tumors were grown for 5 days before the mice were treated by
intravenous injection of 0.9% NaCl containing 5mg/kg human IgG or purified hsCD44s-Fc
fusion proteins every third day until completion of the experiments. Systemic delivery of
hsCD44s-Fc fusion proteins but not human IgG markedly inhibited intracranial growth of
U87MG and U251 cells and significantly (p<0.001) extended median survival of the
experimental mice (Fig 6D left and middle panels). GBM and brain issue were collected at the
time of mouse euthanasia, sectioned, and stained with anti-human IgG antibody to assess the
bio-distribution of hsCD44-Fc fusion proteins. Our results showed that hsCD44-Fc fusion
proteins readily penetrated tumor blood vessels and displayed a remarkable intra-glioma
distribution pattern (Fig 6D, right panel) whereas negligible fusion proteins were observed in
normal adjacent brain tissue, most likely due to the presence of an intact blood-brain-barrier
(Fig 6D). These results suggest CD44-Fc proteins preferentially accumulate within the tumor
tissue, which contains leaky blood vessels. Together, our results demonstrate that hsCD44-Fc
fusion proteins are potentially attractive therapeutic agents for GBM.
Discussion
CD44 promotes malignant glioma progression and is a prime target for anti-glioma therapy
We have demonstrated that CD44 is up-regulated in human GBM and that knockdown of CD44
reduces GBM growth in vivo by inhibiting glioma cell proliferation and promoting apoptosis.
Furthermore, we established for the first time that depletion of CD44 sensitizes GBM cells to
chemotherapeutic agents in vivo and that CD44 antagonists in the form of CD44-specific
shRNAs and CD44-Fc fusion proteins serve as effective GBM growth inhibitory agents in
mouse models.
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Current anti-cancer therapeutic strategies and target selection are heavily concentrated on
frequently mutated kinases whose activity cancer cells become addicted to (46). Although these
approaches are supported by notable successes, they are hampered by emergence of resistant
tumor cells capable of bypassing the targeted signaling pathways through mechanisms that
may be related to the frequently mutated nature of the targets themselves. It is now well
accepted that therapeutic interventions targeting only a single signaling pathway, no matter
how seemingly important, are relatively easily evaded by cancer cells as they acquire new
genetic and epigenetic alterations. An alternative strategy may therefore be to identify versatile
molecules that, unlike the key drivers of oncogenesis, are not central to any single tumor cell
property but participate in multiple functions, including modulation of diverse signaling
pathways and regulation of interactions between tumor cells and the host tissue
microenvironment and tumor cell responses to various forms of stress. Based on their obvious
contributions to tumor growth and progression, such molecules are likely to be up regulated
in malignant tumors but unlikely to be frequently mutated. Selective inhibition of these types
of broad-spectrum functional regulators, especially in combination with chemo- and radiation
therapy as well as other targeted therapies, may therefore achieve more efficacious and/or long
lasting clinical benefits. Our present observations indicate that CD44 may be one such target
in GBM and our preclinical results provide strong support for therapeutic potential of targeting
CD44 and potential usage of CD44 antagonists against malignant glioma.
CD44 functions upstream of the mammalian Hippo signaling pathway and attenuates its
activation induced by oxidative and cytotoxic stress
CD44 has been implicated in the modulation of several signaling pathways (9–12), but no
single intact core pathway that mediates CD44-derived signals has been established thus far.
In Drosophila, merlin functions upstream of the Hippo signaling pathway, but a definitive link
between merlin and the mammalian Hippo pathway homologs has not been established. The
present study demonstrates for the first time that CD44 functions upstream of merlin-MST1/2-
Lats1/2-YAP-cIAP1/2 and two other downstream stress kinases, JNK and/or p38, along with
their effectors, p53, and caspases (Fig 4, S2). It also provides evidence that CD44 plays an
essential novel role in attenuating activation of these stress and apoptotic signaling pathways
induced by chemotherapeutic agents and ROS whereas loss of CD44 function leads to their
sustained activation that promotes apoptosis of GBM cells, which constitutes a plausible
mechanism underlying the chemosensitizing effect of CD44 antagonists.
Resistance to cytotoxic agents and radiation constitutes the major obstacle to successful
treatment of GBM. Increasing evidence suggests the existence of glioma cancer stem cells
(GBM CSC) that are highly resistant to chemo- and radiation therapy and my be responsible
for GBM recurrence following therapeutic intervention (47–48). Although the implication of
CD44 in GBM CSC remains to be elucidated, CD44 is a major cell surface CSC marker in
numerous tumors (9). We show in the present studies that CD44 attenuates the activation of
the Hippo stress/apoptotic signaling pathway in GBM cells and provides a chemoprotective
function in vivo. It will be of interest to determine whether CD44 exerts the same effects in
GBM CSCs.
CD44-Fc fusion proteins and CD44-specific shRNAs are effective therapeutic agents against
malignant glioma
CD44 antagonists, shRNAs against CD44 and hsCD44-Fc fusion proteins when expressed by
GBM cells or delivered systemically, displayed potent anti-GBM activity in mouse models.
Human sCD44-Fc fusion proteins may not only interfere with the function of CD44 expressed
by GBM cells but also with that expressed by host cells infiltrating the tumors, including
immune, inflammatory, and stromal cells, which are known to regulate tumor progression
(43,49). The host inflammatory response can exert both anti- and pro-tumor effects and CD44
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plays an important role in limiting and resolving inflammation (43,50). We found that
overexpression of hsCD44-Fc proteins in GL261 mouse GBM cells inhibited their intracranial
growth in C57BL/6 mice that have intact immunity (data not shown), suggesting the anti-GBM
effect of CD44-Fc fusion proteins were not significantly affected by lack of the adaptive
immunity in Rag-1 mice and are broadly applicable. Furthermore, we have shown that
CD44v3-v10-Fc fusion proteins can be produced as heparan sulfate proteoglycans (S3). It is
not surprising that this fusion protein, which is likely capable of sequestering heparin-binding
growth factors in addition to trapping other CD44 ligands, is the most efficacious one among
the fusion proteins tested and that CD44v3-v10R41A-Fc, which is incapable of binding to HA,
still retained a certain degree of anti-GBM activity (Fig 6C).
Currently available first line treatment options for human GBM are chemo- and radiation
therapy, although both are largely palliative. One hope for a better clinical outcome is to identify
targets that play essential roles in mediating the microenvironment-derived survival signal and
-mediated drug-resistance and that their antagonists sensitize the response of GBM cells to
radiation and chemotherapeutic drugs. Our observation that CD44 plays an important role in
protecting cancer cells from oxidative and cytotoxic stress-induced apoptotic signaling while
enhancing RTK signaling (supplemental Fig 4) suggests that it may serve as an ideal therapeutic
target to sensitize malignant glioma to radiation and chemotherapy, and to the inhibitors of
these RTKs.
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Figure 1. CD44 is up-regulated in human glioma
A, Microarray data sets form oncomine were analyzed for CD44 transcript levels in multiple
glioma tissues compared to normal human brain tissues (study 1, 2, and 4) or to normal white
matter (study 3). B, Representative pictures of CD44 immunohistochemistry performed on 14
GBM tissues and 8 normal human brain samples using anti-CD44 antibody (Santa Cruz). Bar,
50µm. C, Expression of endogenous CD44 in a panel of human glioma cells and normal human
astrocytes (NHAs, ALLCELLS, Inc.) was determined by Western blotting using anti-CD44
antibody (Santa Cruz). 50µg of total proteins were loaded in each lane. Actin was included as
an internal control for loading (lower panels). The molecular weight bars correspond to
197kDa, 110kDa, and 72kDa.
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Figure 2. Knockdown of CD44 expression inhibits subcutaneous growth of U87MG and U251
glioma cells by inhibiting proliferation and promoting apoptosis of the cells in vivo
5 ×106 glioma cells were injected subcutaneously per mouse. A, The effects of CD44
knockdown on subcutaneous growth of U87MG (left) and U251 (right) cells infected with
different shRNA constructs were assessed by measuring tumor volume 5 weeks after tumor
cell implantation. B, Growth rates of the subcutaneous tumors derived from U87MG (left) and
U251 (right) cells infected with different shRNA constructs were determined and expressed
as the mean of tumor volumes (mm3) +/− SD. Six mice were used for each type of transduced
glioma cells in panel A and B. C, Morphology, proliferation and apoptosis status of
subcutaneous gliomas were assessed. Tumor sections were stained with H&E for histology (C,
top panels). In vivo glioma cell proliferation was detected using an anti-BrdU (Roche, C,
middle, first two panels) and an anti-k67 antibody (C, middle, last two panels). Apoptotic GBM
cells in situ were detected using Apoptag kit (Chemicon, C, bottom panels). Bar, in a-d, 50µm
and in e-l, 100 µm.
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Figure 3. Knockdown of CD44 expression inhibits intracranial growth of U87MG and U251 gliomas
and sensitizes responses of the glioma cells to cytotoxic drugs in vivo
A, Bio-luminescence imaging analysis of mice 3, 6, 9, and 13 days following the intracranial
injection of U87MG-TRC-NT, U87MGshRNAmir-NT controls (upper panels), and U87MG-
TRC-CD44#3 and U87MGshRNAmir-CD44#1 (shRNAs effectively knock down CD44
expression, bottom panels). B, Survival rates of mice following intracranial injections of the
transduced U87MG (B, left) and U251 (B, right) cells as detailed in the panels. 15 mice were
used for each type of transduced GBM cells. C, Bioluminescence imaging analysis of mice 6,
9, 13, and 17 days following intracranial injection of U87MG-NT (shRNA controls), or
U87MGshRNA-CD44 (a mixture of shRNAs effectively knocks down CD44 expression).
Mice were injected with or without a single dose of BCNU (10 mg/kg) or TMZ (5mg/kg) 3
days after intracranial injection of the tumor cells. D, Survival rates of mice following
intracranial injections of the transduced U87MG (top) and U251 (bottom) cells are shown in
the panels. 15 mice were used for each treatment.
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Figure 4. CD44 functions upstream of the Hippo signaling pathway and plays an essential role in
attenuating the apoptotic response of glioma cells induced by oxidative stress
Western blots were performed using the cell lysates derived from U87MG-NT cells infected
with a mixture lentiviruses carrying non-targeting shRNAs (A and C), and U87MGshRNA-
CD44 cells infected with a mixture of lentiviruses carrying CD44-specific shRNAs (B and D).
These cells were treated with or without 60µm H2O2 for 30min, 2h, 24h, 48h, and 72h as
indicated in the panels. 100µg of total protein were loaded in each lane. Actin was included as
an internal control for protein loading. The antibodies used against the different signaling
mediators are indicated in the panels.
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Figure 5. CD44 enhances the ErbB and c-Met receptor tyrosine kinase (RTK) mediated activation
of Erk1/2 kinase
Western blots were performed using the cell lysates derived from U87MG-TN (A) and
U87MGshRNA-CD44 cells (B). The serum starved transduced U87MG cells were treated with
or without FBS, NGF (10ng/ml), EGF (2ng/ml), HB-EGF (5ng/ml), betacellulin (BTC, 5ng/
ml), epiregulin (Epr, 5ng/ml), amphiregulin (AR, 5ng/ml), or HGF (20ng/ml) for 12h as
indicated in the panels. The growth factors and antigens to which corresponding antibodies
were used are indicated. 100µg of total protein were loaded in each lane. Actin was included
as an internal control for protein loading.
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Figure 6. Antagonists of CD44, hsCD44v3-v10-Fc, hsCD44v8-v10-Fc, and hsCD44s-Fc, are
effective therapeutic agents against human GBM in mouse models
A, U87MG and U251 cells were transduced with the retroviruses carrying empty vector and
the expression constructs of hsCD44s-Fc, hsCD44v8-v10-Fc, and hsCD44v3-v10 and their
serum free cell culture supernatants were collected and analyzed on Western blots using anti-
CD44 antibody (Santa Cruz) or anti-human IgG antibody. The molecular weight bars
correspond to 199kDa and 116 kDa. B, 2 ×106 of the transduced U87MG and U251 cells were
injected subcutaneously per mouse. Growth rates of the subcutaneous tumors were determined
and expressed as the mean of tumor volume (mm3) +/− SD. Six mice were used for each
construct. C, Survival rates of mice following the intracranial injections of transduced U87MG
(C, left) and U251 (C, right) cells. 15 mice were used for each type of transduced glioma cells
in first two panels and ten mice were used in the last panel. D, Treatment of pre-established
intracranial U87MG and U251 gliomas with intravenous delivery of 5mg/kg purified hsCD44s-
Fc fusion proteins or human IgG every third day. The results show that hsCD44s-Fc but not
human IgG significantly extended the survival of the experimental mice (p<0.001). Six Rag-1
mice were used for each treatment. Distribution of hsCD44s-Fc fusion proteins in intracranial
gliomas and normal adjacent brain tissues are shown. The fusion proteins were detected using
anti-human IgG antibody. Bar, 60 µm.
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